What is Global Contract Pharmaceutical Manufacturing Market?
The Global Contract Pharmaceutical Manufacturing Market is a vast and dynamic sector that plays a crucial role in the healthcare industry. This market involves the outsourcing of pharmaceutical manufacturing by pharmaceutical companies to contract manufacturing organizations (CMOs). These CMOs provide a wide range of services, including drug development, formulation development, stability studies, clinical trial supply, commercial production, and packaging. The primary reason for this outsourcing is to reduce costs and focus more on core competencies like research and development and marketing. The global market for contract pharmaceutical manufacturing was valued at US$ 92940 million in 2022 and is expected to reach US$ 131100 million by 2029, growing at a compound annual growth rate (CAGR) of 5.9% from 2023 to 2029.
Oral, Injectable, API, Other in the Global Contract Pharmaceutical Manufacturing Market:
The Global Contract Pharmaceutical Manufacturing Market is segmented based on the type of product into Oral, Injectable, API, and Others. The Oral segment includes tablets, capsules, and liquids that are consumed orally. The Injectable segment comprises drugs that are administered through injections. The API, or Active Pharmaceutical Ingredient segment, involves the production of the active ingredients used in various pharmaceutical products. The Other segment includes various other forms of drug delivery systems. Among these, API is the largest segment, accounting for about 75% of the market. This is primarily due to the high demand for APIs in the production of various drugs.
Large Enterprise, Small Medium Enterprise in the Global Contract Pharmaceutical Manufacturing Market:
The Global Contract Pharmaceutical Manufacturing Market caters to both Large Enterprises and Small Medium Enterprises (SMEs). Large Enterprises, which include multinational pharmaceutical companies, often outsource their manufacturing processes to CMOs to reduce costs and focus on their core competencies. On the other hand, SMEs, which include start-ups and small-scale pharmaceutical companies, also utilize the services of CMOs due to their lack of manufacturing capabilities. The use of contract manufacturing allows these companies to access high-quality manufacturing processes without the need for significant capital investment.
Global Contract Pharmaceutical Manufacturing Market Outlook:
To summarize, the Global Contract Pharmaceutical Manufacturing Market was valued at US$ 92940 million in 2022 and is projected to reach US$ 131100 million by 2029, growing at a CAGR of 5.9% during the forecast period of 2023-2029. The market is dominated by the API segment, which accounts for about 75% of the market. The market caters to both Large Enterprises and SMEs, providing them with cost-effective and high-quality manufacturing services.
| Report Metric | Details |
| Report Name | Contract Pharmaceutical Manufacturing Market |
| Accounted market size in 2022 | US$ 92940 in million |
| Forecasted market size in 2029 | US$ 131100 million |
| CAGR | 5.9% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | Catalent, DPx, Lonza, Piramal Healthcare, Aenova, Jubilant, Famar, Boehringer Ingelheim, Fareva Holding, AbbVie, Nipro Corp, Vetter, Sopharma, DPT Laboratories, Recipharm, NextPharma, Dishman, Aesica |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
